I-Mab (NASDAQ:NBP) Raised to Hold at Wall Street Zen

I-Mab (NASDAQ:NBP) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other research analysts have also issued reports on the stock. Weiss Ratings upgraded shares of I-Mab from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 1st. HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of I-Mab in a research report on Thursday. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $9.00.

I-Mab Price Performance

Shares of NBP opened at $2.00 on Friday. The stock has a 50 day simple moving average of $1.78. I-Mab has a 12-month low of $1.46 and a 12-month high of $6.79. The firm has a market cap of $231.30 million, a PE ratio of -5.56 and a beta of 1.47.

I-Mab (NASDAQ:NBP) last released its earnings results on Thursday, August 20th. The company reported ($0.16) EPS for the quarter. On average, equities research analysts forecast that I-Mab will post -0.3 earnings per share for the current fiscal year.

Institutional Trading of I-Mab

An institutional investor recently bought a new stake in I-Mab stock. Brooklyn Investment Group bought a new position in I-Mab (NASDAQ:NBP) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 12,715 shares of the company’s stock, valued at approximately $51,000. 38.38% of the stock is owned by institutional investors.

I-Mab Company Profile

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.